METHOD OF NEOADJUVANT TREATMENT OF PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER Russian patent published in 2018 - IPC A61K31/282 A61K31/7064 A61K38/21 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular oncology, and can be used to treat patients with invasive and locally advanced cervical cancer. Method includes the combination of plasmapheresis with neoadjuvant chemotherapy and immunotherapy. Before the start of chemotherapy, a gravitational discrete plasmapheresis session is performed with the MCS+ “Gemonetics” device in the PPP protocol mode with a perfusion speed of 40 ml/min and the rate of blood separation V=4,800 rpm, the volume of plasma extraction is 600–800 ml, as solutions of hydroxyethyl starch 10 % are injected intravenously as plasma substitution solutions, albumin 5 %, crystalloid solution, after 4–5 hours after the end of the plasmapheresis session, 1 ml of “Allokin-alpha” is injected subcutaneously. On day 3 of the treatment intravenously, cisplatin is administered dropwise at a dose of 75 mg/m² against a background of hyperhydration, forced diuresis, under the cover of antiemetics, intravenously stream bleomycetin 20 mg/m² and 1 ml of “Allokin-alpha” is injected subcutaneously. On the 5^th day of treatment iv bleomycetin is injected intravenously at a dose of 20 mg/m², 1 ml of “Allokin-alpha” is injected subcutaneously, at 7, 9, 11 days of treatment, 1 ml of “Allokin-alpha” is administered.

EFFECT: use of the invention allows to shorten the duration of neoadjuvant treatment, reduce the number of necessary cycles of preoperative therapy by directly affecting the virus-induced tumor cells, overcoming the resistance of the tumor to cytostatics, achieving a more rapid clinical effect in the form of regression of the primary tumor focus, ensure synergism and prolongation of the activity of anti-stress protection mechanisms, increase antitumor resistance and activate immune defense of the organism.

1 cl, 1 ex